PredilifeFRA:0GA -5.88%29 FCF Yield % is -31.01 as of Jul. 08, 2026. GuruFocus rates FRA:0GA with a GF Score™ of 29/100 and a GF Value™ of €18.80 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Predilife ranks worse than 85.98% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Predilife's FCF Yield % or its related term are showing as below:
FRA:0GA'
s FCF Yield % Range Over the Past 10 Years
Min: -32.79 Med: -14.58 Max: -5.84
Current: -31.01
During the past 10 years, the highest FCF Yield % of Predilife was -5.84%. The lowest was -32.79%. And the median was -14.58%.
FRA:0GA's FCF Yield % is ranked worse than 85.98% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.345
vs FRA:0GA: -31.01
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Predilife FCF Yield % Related Terms
Predilife FCF Yield % Historical Data
* Premium members only.
The historical data trend for Predilife's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Predilife's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predilife FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Predilife's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Predilife's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predilife (FRA:0GA) has a FCF Yield % of -31.01 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Predilife and its competitors. According to the industry distribution chart, Predilife ranks #184 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 86%.
Is Predilife's FCF Yield % too high?
Predilife's current FCF Yield % is -31.01. Based on the distribution chart, Predilife ranks #184 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Predilife has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Predilife's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Predilife ranks #184 out of 214 companies for FCF Yield %. This places Predilife in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Predilife and its competitors. Predilife's current FCF Yield % is -31.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predilife stock overvalued right now?
Based on GuruFocus' analysis, Predilife (FRA:0GA) is currently considered Possible Value Trap. The stock's GF Value™ is €18.80, compared to a current price of €2.08 — trading 88.9% below its estimated fair value. The current FCF Yield % is -31.01. Predilife's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Predilife (FRA:0GA), the current FCF Yield % is -31.01 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Predilife (FRA:0GA) Overvalued in 2026?
Based on GuruFocus' analysis, Predilife stock appears to be undervalued.
The current stock price of €2.08 is trading 88.9% below its estimated GF Value™ of €18.80.
GuruFocus considers Predilife to be Possible Value Trap.
Key valuation signals for FRA:0GA:
FCF Yield %: -31.01
GF Value™: €18.80 vs. price of €2.08 (88.9% below fair value)
No single metric tells the full story. See the FRA:0GA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Predilife SA develops solutions for predictive medicine, combining medical techniques (genetic tests, medical imaging) and mathematical models with a large amount of statistical data, which allows each individual to define their risk profile for the occurrence of various serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.
29GF Score
Get the complete analysis for FRA:0GA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0GA has been successfully added to your 
